|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luke C, Tracey E, Stapleton A and Roder D:
Exploring contrary trends in bladder cancer incidence, mortality
and survival: implications for research and cancer control. Intern
Med J. 40:357–362. 2010. View Article : Google Scholar
|
|
3
|
Zuiverloon TC, Nieuweboer AJ, Vekony H,
Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response
to bacillus Calmette-Guerin immunotherapy in high-risk bladder
cancer patients: a systematic review. Eur Urol. 61:128–145. 2012.
View Article : Google Scholar
|
|
4
|
Mattick JS: RNA regulation: a new
genetics? Nat Rev Genet. 5:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Itesako T, Seki N, Yoshino H, et al: The
microRNA expression signature of bladder cancer by deep sequencing:
the functional significance of the miR-195/497 cluster. PLoS One.
9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fuse M, Kojima S, Enokida H, et al: Tumor
suppressive microRNAs (miR-222 and miR-31) regulate molecular
pathways based on microRNA expression signature in prostate cancer.
J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidaka H, Seki N, Yoshino H, et al: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
10
|
Nohata N, Hanazawa T, Kikkawa N, et al:
Tumour suppressive microRNA-874 regulates novel cancer networks in
maxillary sinus squamous cell carcinoma. Br J Cancer. 105:833–841.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ichimi T, Enokida H, Okuno Y, et al:
Identification of novel microRNA targets based on microRNA
signatures in bladder cancer. Int J Cancer. 125:345–352. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshino H, Chiyomaru T, Enokida H, et al:
The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishikawa R, Goto Y, Kojima S, et al:
Tumor-suppressive microRNA-29s inhibit cancer cell migration and
invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014.PubMed/NCBI
|
|
14
|
Kojima S, Enokida H, Yoshino H, et al: The
tumor-suppressive microRNA-143/145 cluster inhibits cell migration
and invasion by targeting GOLM1 in prostate cancer. J Hum Genet.
59:78–87. 2014. View Article : Google Scholar
|
|
15
|
Kinoshita T, Nohata N, Hanazawa T, et al:
Tumour-suppressive microRNA-29s inhibit cancer cell migration and
invasion by targeting laminin-integrin signalling in head and neck
squamous cell carcinoma. Br J Cancer. 109:2636–2645. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshino H, Enokida H, Itesako T, et al:
Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in
renal cell carcinoma. Cancer Sci. 104:1567–1574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamasaki T, Yoshino H, Enokida H, et al:
Novel molecular targets regulated by tumor suppressors microRNA-1
and microRNA-133a in bladder cancer. Int J Oncol. 40:1821–1830.
2012.PubMed/NCBI
|
|
18
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21.
2012.PubMed/NCBI
|
|
19
|
Kojima S, Chiyomaru T, Kawakami K, et al:
Tumour suppressors miR-1 and miR-133a target the oncogenic function
of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J
Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
20
|
Kawakami K, Enokida H, Chiyomaru T, et al:
The functional significance of miR-1 and miR-133a in renal cell
carcinoma. Eur J Cancer. 48:827–836. 2012. View Article : Google Scholar
|
|
21
|
Nohata N, Hanazawa T, Kikkawa N, et al:
Identification of novel molecular targets regulated by tumor
suppressive miR-1/miR-133a in maxillary sinus squamous cell
carcinoma. Int J Oncol. 39:1099–1107. 2011.PubMed/NCBI
|
|
22
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b
are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer.
Cancer Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors and directly
regulate FSCN1 expression in bladder cancer. Br J Cancer.
102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishteiwy RA, Ward TM, Dykxhoorn DM and
Burnstein KL: The microRNA-23b/-27b cluster suppresses the
metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 7:e521062012. View Article : Google Scholar
|
|
25
|
Husted S, Sokilde R, Rask L, et al:
MicroRNA expression profiles associated with development of drug
resistance in Ehrlich ascites tumor cells. Mol Pharm. 8:2055–2062.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park YT, Jeong JY, Lee MJ, et al:
MicroRNAs overexpressed in ovarian ALDH1-positive cells are
associated with chemoresistance. J Ovarian Res. 6:182013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Inoguchi S, Seki N, Chiyomaru T, et al:
Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation
through targeting FOXM1 in bladder cancer. FEBS Lett.
588:3170–3179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shaw AT, Hsu PP, Awad MM and Engelman JA:
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat
Rev Cancer. 13:772–787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59:21–26.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oda K, Matsuoka Y, Funahashi A and Kitano
H: A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol. 1:2005.0010. 2005. View Article : Google Scholar
|
|
31
|
Chow NH, Liu HS, Lee EI, et al:
Significance of urinary epidermal growth factor and its receptor
expression in human bladder cancer. Anticancer Res. 17:1293–1296.
1997.PubMed/NCBI
|
|
32
|
Mellon K, Wright C, Kelly P, Horne CH and
Neal DE: Long-term outcome related to epidermal growth factor
receptor status in bladder cancer. J Urol. 153:919–925. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bue P, Wester K, Sjostrom A, et al:
Expression of epidermal growth factor receptor in urinary bladder
cancer metastases. Int J Cancer. 76:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O’Brien LE, Tang K, Kats ES,
Schutz-Geschwender A, Lipschutz JH and Mostov KE: ERK and MMPs
sequentially regulate distinct stages of epithelial tubule
development. Dev Cell. 7:21–32. 2004. View Article : Google Scholar
|
|
35
|
Graziani A, Gramaglia D, Cantley LC and
Comoglio PM: The tyrosine-phosphorylated hepatocyte growth
factor/scatter factor receptor associates with phosphatidylinositol
3-kinase. J Biol Chem. 266:22087–22090. 1991.PubMed/NCBI
|
|
36
|
Boccaccio C, Ando M, Tamagnone L, et al:
Induction of epithelial tubules by growth factor HGF depends on the
STAT pathway. Nature. 391:285–288. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Monga SP, Mars WM, Pediaditakis P, et al:
Hepatocyte growth factor induces Wnt-independent nuclear
translocation of beta-catenin after Met-beta-catenin dissociation
in hepatocytes. Cancer Res. 62:2064–2071. 2002.PubMed/NCBI
|
|
38
|
Cheng HL, Trink B, Tzai TS, et al:
Overexpression of c-met as a prognostic indicator for transitional
cell carcinoma of the urinary bladder: a comparison with p53
nuclear accumulation. J Clin Oncol. 20:1544–1550. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miyata Y, Sagara Y, Kanda S, Hayashi T and
Kanetake H: Phosphorylated hepatocyte growth factor receptor/c-Met
is associated with tumor growth and prognosis in patients with
bladder cancer: correlation with matrix metalloproteinase-2 and -7
and E-cadherin. Hum Pathol. 40:496–504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goldman JW, Laux I, Chai F, et al: Phase 1
dose-escalation trial evaluating the combination of the selective
MET (mesenchymalepithelial transition factor) inhibitor tivantinib
(ARQ 197) plus erlotinib. Cancer. 118:5903–5911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Vandenboom TG II, Wang Z, et al:
miR-146a suppresses invasion of pancreatic cancer cells. Cancer
Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chiyomaru T, Yamamura S, Fukuhara S, et
al: Genistein up-regulates tumor suppressor microRNA-574-3p in
prostate cancer. PLoS One. 8:e589292013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Acunzo M, Visone R, Romano G, et al:
miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by
downregulating miR-221 and 222. Oncogene. 31:634–642. 2012.
|
|
46
|
Yan D, da Dong XE, Chen X, et al:
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma
development. J Biol Chem. 284:29596–29604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Taulli R, Bersani F, Foglizzo V, et al:
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma
growth in xenotransplanted mice by promoting myogenic
differentiation. J Clin Invest. 119:2366–2378. 2009.PubMed/NCBI
|
|
48
|
Acunzo M, Romano G, Palmieri D, et al:
Cross-talk between MET and EGFR in non-small cell lung cancer
involves miR-27a and Sprouty2. Proc Natl Acad Sci US A.
110:8573–8578. 2013. View Article : Google Scholar
|
